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Background: Tamoxifen has anti-oestrogenic and anti-tumour activity in the breast, but is oestrogenic and carcinogenic in the
endometrium. It can induce experimental tumours by both hormonal and DNA-damaging mechanisms, but its carcinogenic mode
of action in human endometrium remains unclear.
Methods: We investigated whether an epigenetic mechanism, involving promoter hypermethylation of the gene for the DNA
repair enzyme MGMT (O6-methylguanine DNA methyltransferase), was associated with K-RAS, TP53 and PTEN mutations in
endometrial tumours from women treated with tamoxifen (TAM, n¼ 30) or unexposed to the drug (EC, n¼ 38).
Results: There were significant (Po0.05) differences in tumour grade between the TAM and EC groups, with more favourable
morphology in the latter. K-RAS mutations, predominantly G4A, occurred in small numbers in both groups. TP53 mutations were
of mainly A4G, C4T and indel modifications in both groups, but more frequent in TAM cases. PTEN mutations dominated in EC
tumours and were of the type that has large impact on protein function, such as indel or nonsense mutations. These observations
alongside the mutational spectrum in PTEN suggest that the malignancies arise from different backgrounds, hence pointing to an
effect of tamoxifen. Both groups displayed MGMT promoter hypermethylation. This coincided with mutations more frequently in
the TAM (78%) than in the EC (50%) group, even though there were significantly (Po0.05) fewer mutations and methylations in
TAM cases.
Conclusions: Although the difference in coincidence did not reach significance with the current sample size, the findings suggest
that epigenetic processes may play a role in the way tamoxifen induces endometrial cancer.
Endometrial cancer is the fourth most common cancer in women
in industrialised countries, with many risk factors including the use
of exogenous oestrogens and certain drugs, such as tamoxifen
(Fisher et al, 1998). Tamoxifen is a selective oestrogen receptor
modulator, which acts antagonistically in oestrogen-dependent breast
cancer by competing for the oestrogen receptor (ER), thereby forming
a nuclear complex that recruits co-repressors to stop oestrogen-driven
transcription. This decreases DNA synthesis and causes G0/G1 phase
arrest of the cell cycle (Shang et al, 2000). In human endometrium,
however, tamoxifen displays oestrogenic activity.
*Correspondence: Dr E Nagy; E-mail: eszter.nagy@kcl.ac.uk
Received 21 February 2014; accepted 23 April 2014; published online 22 May 2014
& 2014 Cancer Research UK. All rights reserved 0007 – 0920/14
FULL PAPER
Keywords: tamoxifen; epigenetics; hypermethylation; endometrial cancer; TP53; K-RAS; PTEN
British Journal of Cancer (2014) 110, 2874–2880 | doi: 10.1038/bjc.2014.263
2874 www.bjcancer.com |DOI:10.1038/bjc.2014.263
Tamoxifen gives rise to DNA adducts and liver cancer in both
male and female rats (Davis et al, 2000). In rats, the minor
metabolite alpha-OH-tamoxifen is a substrate for hydroxysteroid
sulphotransferase a, which leads to bioactivation in the liver,
whereas in humans the major metabolite 4-OH-tamoxifen is
conjugated by oestrogen sulphotransferases leading to detoxifica-
tion (Chen et al, 2002). This interspecies difference in tamoxifen
metabolism may partly explain why the compound is more toxic
for rats compared to humans. Nonetheless, the potential neoplastic
effects of tamoxifen in human endometrium have been largely
unexplored at the molecular level.
In humans, a major circulating inactive form of plasma
oestrogen is oestrogen sulphate (E1S and E2S) that can be activated
by intra-tumoural steroid sulphatases, thereby exerting additional
in situ hormonal activity in oestrogen-dependent breast cancers
(Chetrite et al, 2000). Similar observations have been made in
endometrial tumours displaying increased steroid sulphatase and
lowered oestrogen sulphotransferase activity (Utsunomiya et al,
2004), and in endometrial cancer cells where tamoxifen was shown
to perturb the balance of oestrogen-metabolising enzymes and
disposition of oestrogen metabolites (Williams-Brown et al, 2011).
Metabolism of tamoxifen also involves formation of quinone
metabolites, which can oxidise and alkylate cellular macromole-
cules in vivo (Zhang et al, 2000). O6-methylguanine DNA
methyltransferase (MGMT) is responsible for repairing alkylation
DNA damage and also has a possible role in inhibiting ER-
mediated cell proliferation (Teo et al, 2001). In addition, certain
polymorphic variants of MGMT may influence endometrial cancer
risk (Han et al, 2006). Expression of MGMT is in part controlled
through epigenetic processes such as hypermethylation of the
promoter region of the gene, which can lead to inactivation of the
repair pathway (Esteller et al, 1999), but evidence for the role of
MGMT in endometrial cancer is conflicting (Furlan et al, 2006;
Rimel et al, 2009).
K-RAS, PTEN and TP53 are often mutated in endometrial
cancer, at frequencies that vary with tumour grade (Liu, 2007;
Bansal et al, 2009). The aim of this project was to investigate
associations between tamoxifen exposure, MGMT promoter
hypermethylation and mutations in TP53, PTEN and K-RAS in
endometrial tumours and tissue, in order to shed light on the
carcinogenic mode of action of tamoxifen in humans.
MATERIALS AND METHODS
Patients. All samples were from cancer cases and subdivided
according to the following criteria:
TAM (n¼ 30): endometrial tumours from women who had
taken tamoxifen; average age 69.4±11.2 years; 10 with matching
blood samples.
EC (n¼ 38): endometrial tumours from patients not treated
with tamoxifen; average age 67.0±9.4 years; 24 with matching
blood samples.
Treatment with tamoxifen ranged from 4 months to 20 years at
20mg per day. In the majority of cases the tamoxifen use was
restricted to approximately 60 months duration. Extended usage of
tamoxifen was only in two cases with breast cancer recurrences.
The samples were from patients undergoing gynaecological
surgery in the Royal Preston Hospital of Lancashire Teaching
Hospitals NHS Foundation Trust in Preston between January 2006
and August 2012. Ethical committee approvals were obtained
(Local Research Ethical Committee (LREC) approval no. 05/
Q1302/83 and the Research and Ethics Committee (REC) approval
no. 10/H0308/75). The consenting patients were between the ages
of 37 and 90 years. Samples were formalin-fixed and paraffin-
embedded (FFPE) and/or flash frozen (FF). Histopathology was
performed to determine the tumour type and grade. Shavings of
the FFPE blocks and/or small pieces of the FF tissues, as well as
frozen blood, were sent to King’s College London for DNA
isolation.
One patient in each group was found to have a silent germline
mutation in TP53. These patients were excluded from the data
compilation (Figures and Tables) and statistical calculation,
although still included in Supplementary data.
Methylation specific-PCR analysis. DNA was extracted from
triplicate shavings (10-mm thickness) from tumour samples
containing less than 10% normal tissue using a QIAamp DNA
FFPE Tissue Kit (Qiagen GmbH, Hilden, Germany) according to
the manufacturer’s instructions. The extracted DNA was measured
spectrophotometrically for purity and concentration, and 1 mg
(where possible) was bisulphite-treated using the Epitect Bisulfite
Kit (Qiagen GmbH, Hilden, Germany). The bisulphite-converted
DNA was amplified by PCR for the selected promoter region with
the following primers synthesised in 25 nmol scale by Invitrogen
(Carlsbad, CA, USA):
MGMT-MF: TTTCGACGTTCGTAGGTTTTCGC
MGMT-MR: GCACTCTTCCGAAAACGAAACG
MGMT-UF: TTTGTGTTTTGATGTTTGTAGGTTTTTGT
MGMT-UR: AACTCCACACTCTTCCAAAAACAAAACA
Primers were diluted in distilled water to 300 ng ml 1 and the
following PCR mixture was prepared; 5ml of 10PCR reaction
buffer, 5 ml of 50mM MgCl2 and 0.2 ml Platinum Taq (1U; all from
Invitrogen) was mixed with 5ml 10mM dNTP-mix (Qiagen),
2 1 ml primer (forward and reverse), 10 ml DNA template and
22.8 ml of distilled water to a total volume of 50 ml. Bisulphite-
converted methylated and unmethylated human DNA, as well as
non-converted unmethylated DNA that was converted along with
the samples, and pure water, were included with each PCR analysis
as positive or negative controls.
The thermocycler was programmed for a 5-min hot start at
95 1C, followed by 40 cycles of 94 1C for 40 s, 59 1C for 40 s and
72 1C for 40 s, and finally a 10-min elongation step at 72 1C. The
PCR products were separated on 3% agarose at 140V and
visualised with EtBr. The bisulphite treatment and PCR amplifica-
tion were carried out in triplicate; if a methylated band was
observed at least two out of three times for a given sample, then it
was deemed to be positive for methylation.
Sequencing. DNA was isolated from FFPE tissues as described
above, and from FF tissues and blood using a DNeasy Blood &
Tissue kit, (Qiagen). The purified DNA was measured for
concentration and aliquots were portioned into 96-well plates
and immediately frozen at  80 1C. Sequencing was performed by
Beckman Coulter Genomics (United States) on K-RAS exon 1–4,
PTEN exons 1–9 and TP53 exons 4–11.
Statistical analysis. Statistical analysis was performed using a two-
tailed Z-test at the 95% confidence level by evaluating the
proportions of given occurrences in the different patient groups
(TAM and EC). Differences were statistically significant when
Pp0.05.
RESULTS
Tumour histology and grading. Patients with tamoxifen-asso-
ciated endometrial cancer (TAM) had significantly lower occur-
rence (Pp0.05) of type I tumours than those in the non-exposed
(EC) group with 5 out of 29 (17%) and 17 out of 37 (46%),
respectively (Table 1). TAM cases had more type II tumours of
predominantly serous, carcinosarcoma and mixed carcinoma,
whereas in the EC group these were mainly grade 3 endometrioid
carcinomas followed by clear cell and carcinosarcoma (Table 1).
Tamoxifen and epigenetics in endometrial cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.263 2875
Grouping together the endometrioid tumours of all grades
(G1–G3), a significant (Pp0.05) overrepresentation of 23 out of
27 (62%) was found among the EC cases. There was also a
significant difference (Pp0.05) between these two groups with
respect to other diverse lesions, including hyperplasia, polyps,
inactive, menstrual, proliferative and secretory endometrium,
which were completely absent from the EC group, but represented
about 4 out of 29 (14%) of the malignancies among the TAM cases.
MGMT promoter hypermethylation. Patients scored positive for
promoter hypermethylation in both groups (Table 2), with TAM 9
out of 29 (31%) and EC 14 out of 37 (38%). There was no statistical
difference between any of the groups and no correlation between
the type or grade of tumours and MGMT promoter hypermethyla-
tion (Supplementary data).
Mutation analysis
Overall mutations. Counting the number of patients with
mutations, regardless of type of gene or multiple mutations in
the same gene, revealed no difference between the two tumour
groups. There was a trend in higher occurrence of methylations or
mutations in the EC as compared to the TAM group, which was
significant (Pp0.05) when adding up patients with either of the
modifications present. The reverse was observed in patients who
exhibited both a mutation and methylation (Table 2). Thus,
although not statistically verified at the 95th percentile, a closer
look at how many patients with methylation also exhibited
mutations showed that this occurrence was higher in the TAM
compared with the EC group, with 7 of 9 (78%) and 7 of 14 (50%),
respectively (Table 2).
Specific mutations. K-RAS mutations were found in both groups
and were mainly of the missense type and distributed over codons
11–13 in exon 2; four in TAM and two in EC (Table 3). The
mutations in the TAM group consisted of one G4T transversion
and three G4A transitions. In the EC group, the K-RAS mutations
were one G4A transition at codon 13 and a T4C transversion
(Supplementary data).
TP53 mutations occurred in both groups to a similar extent
(34% in TAM and 38% in EC) and were of diverse types (Table 3).
The tumour groups displayed mainly missense or indel alterations,
with the addition of a few nonsense mutations in EC, and
predominantly clustering within the central DNA-binding core
domain within residues 102–292. Some of the missense mutations
designated with SNP ascension numbers were found to be
associated to Li-Fraumeni syndrome (see Discussion). Two
patients, one in each group, had a germline silent mutation in
TP53 (Arg213Arg rs1800372), which was confirmed in corre-
sponding blood samples (Supplementary data).
Table 1. Tumour histology and grading of morphologies found in the
patient groups of tamoxifen and unexposed, categorised into Type I,
Type II or others
Endometrial tumours N
TAM
29
EC
37
TYPE I
G1 endometroid 15 3 12
G2 endometroid 7 2 5
TYPE II
G3 endometroid 7 1 6
Uterine papillary serous carcinoma 7 5 2
Clear-cell endometroid 4 1 3
Carcinosarcoma 14 8 6
Mixed carcinoma 8 5 3
OTHERS
Simple hyperplasia 1 1 0
Complex atypical hyperplasia 1 1 0
Endometrial polyp 0 0 0
Endometrial polyp with stromal hyperplasia 1 1 0
Inactive endometrium 0 0 0
Menstrual endometrium (progestagen effect) 0 0 0
Proliferative 1 1 0
Secretory 0 0 0
Table 3. Specific types and numbers of mutations found in the different
groups
Groups Gene Spec mut. Type of mut.
TAM
K-RAS 14%
(4 of 29)
G4A (3 of 4)
G4T (1 of 4)
P53 34%
(10 of 29)
A4G (2 of 10)
A4T (1 of 10)
C4T (2 of 10)
G4A (1 of 10)
G4T (1 of 10)
Indel (3 of 10)
PTEN 21%
(6 of 29)
C4T (1 of 6)
Indel (5 of 6)
EC
K-RAS 5%
(2 of 37)
G4A (1 of 2)
T4C (1 of 2)
P53 38%
(14 of 37)
A4G (3 of 14)
C4T (6 of 14)
G4A (1 of 14)
T4A (1 of 14)
Indel (3 of 14)
PTEN 59%
(22 of 37)
A4C (1 of 22)
A4G (1 of 22)
A4T (2 of 22)
C4A (2 of 22)
C4G (2 of 22)
C4T (4 of 22)
G4T (2 of 22)
T4A (1 of 22)
T4G (1 of 22)
T4C (1 of 22)
Indel (5 of 22)
Abbreviations: EC¼ unexposed to the drug; TAM¼ tamoxifen. The number of mutations is
based on each individual mutation found in the patients, which includes multiple mutations
in the same gene.
Table 2. Percentage of MGMT promoter hypermethylation, mutation,
both, either or neither in the TAM and EC groups
Groups
Total
(n) Methyl. Mutation Both Eithera Neithera
TAM 29 31%
(9 of 29)
52%
(15 of 29)
24%
(7 of 29)
62%
(17 of 29)
41%
(12 of 29)
EC 37 38%
(14 of 37)
68%
(25 of 37)
19%
(7 of 37)
86%
(32 of 37)
14%
(5 of 37)
a
Indicates that there is a significant (Po0.05) difference between the tamoxifen (TAM) and
unexposed to the drug (EC) groups.
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PTEN was extensively mutated in the EC group (Table 3) and
found within varying grades and types of tumours and of the sort
that has great impact on protein function; i.e., truncated via a stop-
codon, or frameshift through either insertion or deletion. In fact,
out of the 22 PTEN mutations observed in the EC group, 11 were
either stop or indel (supplementary data). Only six patients from
the TAM group displayed PTEN mutations, out of which five were
indel and just one was a silent mutation (Table 3). Most alterations
occurred in exon 5 (photsphatase domain and core motif), 7–8 and
one mutation each in exons 3, 4, 6 and 9 (C-terminal region). No
correlation to methylation status was found in any of the cases.
The mutation spectrum of the two tumour groups showed that
the most commonly mutated gene following tamoxifen treatment
was TP53, with A4G (27%), C4T (20%) and indel (30%)
modifications (Figure 2). In the PTEN gene, indel was by far the
most common alteration with 83%. The EC group displayed high
degree of mutation in both TP53 and PTEN. In TP53, the most
prominent base-change was C4T (43%), followed by A4G (22%)
and indel (21%), and occurred mainly in tumours of non-
endometrioid character. In PTEN, C4T (18%) and indel (23%)
dominated, and over half of all mutations were found in
endometrioid tumours (Supplementary data).
Interpretation. Epidemiological studies have shown an increased
risk of endometrial cancer with tamoxifen exposure, correlating
risks ranging from 2.53 to 7.5 with length of exposure/treatment
(van Leeuwen et al, 1994; Fisher et al, 1998). The mechanisms of
action are yet to be fully evaluated; despite the demonstration of
the DNA adduct forming capacity of metabolically activated
tamoxifen in animals and in some experimental systems, there is
conflicting evidence on the genotoxicity of tamoxifen in humans
(Phillips, 2001; Kim et al, 2004; Singh et al, 2007, 2008). Here we
aimed to investigate if there was a possible connection between
tamoxifen treatment, promoter hypermethylation of MGMT and
mutations in genes known to play a role in endometrial cancer.
Tumour histology and grading. High-grade malignancies were
more frequent in the TAM group compared to EC, which consisted
mainly of type I category malignancies of endometrioid character
and G1–G2 morphology (Table 1), corroborating previous
observations that women who underwent tamoxifen treatment
for breast cancer and subsequently developed uterine cancers had
higher-grade tumours with less favourable prognosis (Magriples
et al, 1993; van Leeuwen et al, 1994). A possible bias towards high-
grade tumours at medical centres that are better equipped for
treating more severe cases is disputed based on the scarcity of the
tamoxifen-exposed cases even with influx of large patient numbers,
the endeavours of peripheral centres to report and collect all
available samples, and that none of the patients opted out of the
study despite the length of time. In addition, the medical histories
of the patients were taken into consideration, where previous/
adjuvant treatments in patients with breast cancer in the TAM
group involved either radiotherapy or a combination of 5FU/
epirubicin/cyclophosphamide. These therapies and this combina-
tion of drugs have not been reported in the literature to be
associated with increased risk of endometrial cancer.
When assessing the occurrence of type I tumours, there was a
statistically significant difference (Pp0.05) between the TAM and
EC groups, which also held true when evaluating the occurrence of
all endometrioid morphologies as a whole (G1–G3; Table 1). It is
reported that the majority of endometrial cancers (70–80%),
designated as type I carcinomas, follow the oestrogen-related
pathway and seemingly arise in the background of hyperplastic
endometrium with endometrioid differentiation (Liu, 2007).
However, many endometrial carcinomas are overlapping in their
clinical, morphologic, immunohistochemical and molecular fea-
tures between types I and II. Lesions with various histologies
including polyps, hyperplasia, late/mid-secretory and proliferative
endometrium, and progesterone effect were only observed in the
TAM group. Many of these are normal features and are universal
components of the menstrual cycle, although some forms of
hyperplasia (especially complex atypical) can be premalignant.
Polyps are, for instance, not precancerous, but still occur more
commonly in women on tamoxifen (Biron-Shental et al, 2003).
MGMT promoter hypermethylation. There was no statistical
difference between groups with regard to MGMT promoter
hypermethylation, which was seen in 9 out of 29 (31%) and 14
out of 37 (38%) cases, in TAM and EC groups, respectively
(Table 2). There is some support for this in the literature, but also
some studies that contradict our finding. Rimel et al (2009) found
an absence of MGMT promoter hypermethylation in 120
endometrial cancer cases, which was also supported by previous
findings in a small number (n¼ 17) of endometrial cancers
(Jacinto and Esteller, 2007). On the other hand, in a study
involving synchronous ovarian and endometrial primary tumours
there was a similar rate of MGMT promoter hypermethylation to
what we report here (Furlan et al, 2006). One aspect to consider is
methodology where it can be argued that studies finding positive
methylation were done with MS-PCR, which may increase
sensitivity and methylation-positive cases with increasing cycles
of amplification (Shen et al, 2005). However, different methodo-
logies (MS-PCR and/or combined bisulphite restriction analysis)
have been used on various DNA sources, often in parallel, and
results were found to be consistent (Xiong and Laird, 1997; Shen
et al, 2005; Cheng et al, 2010). In addition, primer design needs to
meet certain criteria (Herman et al, 1996; Brandes et al, 2007) and
proper controls need to be added in the analysis to avoid problems
of false-positives. Hence, we optimised the melting temperature
with gradient PCR, using both converted and non-converted DNA
and water to minimise false-positives and these controls were
included in every amplification step from then on (Figure 1B). The
quality of the DNA does not explain discordance with the
literature, as methylation was also observed in both groups and
no difference in the extent of methylation was seen between FFPE
or flash-frozen tissues. When comparing methylation to tumour
type there were no significant correlations.
TAM
EC
Ctrl
Figure 1. Examples of MS-PCR analysis (A; showing the first lane of
gels, including 10 patient samples of each group). ‘M’ represents
methylated bands and ‘U’ unmethylated. Controls (B) were used at
each analysis with BC-U being unmethylated human DNA that was
bisulphite converted during sample workup procedures to assess the
success of the conversion step. ‘C–U’ and ‘C–M’ were commercially
available bisulphite converted unmethylated and methylated human
DNA, respectively. ‘DNA’ represents non-converted human DNA.
The H2O samples were lacking DNA of any sort in the PCR mixture. Note
that close to the bottom line of the ladder corresponding to about 50bp,
bands can be seen. These are primer dimers. The product bands for both
‘M’ and ‘U’ are around 100bp with only minor differences.
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Mutation analysis. K-RAS mutations are fairly common
(10–30%) in endometrial cancer, and are mostly found in lower-grade
tumours (Liu, 2007). Tamoxifen gave rise to G4T transversions at
codon 12 in exon 2 in the K-RAS gene in rat liver (Davies et al,
1999), whereas in human endometrium these mutations are less
frequent than G4A transitions (Hachisuga et al, 2005). In our
study, the only type of K-RAS mutation, which has been associated
to adverse outcome, was G4A transition resulting in missense
mutations (Gly4Ser or Gly4Asp). This type of mutation at codon
12 has been observed in endometrial cancer following tamoxifen
treatment (Prasad et al, 2005; Wallen et al, 2005), but is also
common in colon (Brink et al, 2003; Wu et al, 2005) and pancreatic
cancer (Hruban et al, 1993). Some studies show a possible
association between MGMT promoter hypermethylation and
K-RAS G4A transition with regard to colon cancer (Shen et al,
2005; Nagasaka et al, 2008). Even if the rate of K-RAS mutations in
our study falls within the reported values (5–14%, Table 3), no
conclusions can be drawn with regard to mutation type and
methylation. One patient from the EC group displayed a T4C
transition at codon 173 (rs17473423), but it is a common
polymorphism and no convincing data have been found associat-
ing it with any adverse outcome, although it was seen in a few cases
of Noonan Syndrome, which is a relatively common autosomal
dominant congenital disorder (Yamamoto et al, 2007).
In a study by Turbiner et al (2008), K-RAS mutations appeared
to be more common among endometrial carcinomas in patients
with history of tamoxifen exposure (21%) compared with
informative endometrial carcinomas (11%), and were comparably
low in both tumour-adjacent groups, although the difference was
not statistically significant. Previous reports also found that
endometrial polyps in patients treated with tamoxifen had a
significantly higher frequency of K-RAS mutations compared with
sporadic endometrial hyperplasia (Hachisuga et al, 2003) and
treatment with tamoxifen or toremifene gave rise to de novo K-RAS
mutation in a seemingly normal endometrial tissue (Wallen et al,
2005). Accordingly, our study showed K-RAS mutations in 4 out of
20 (20%) mutations among TAM patients, and 2 out of 38 (5%) in
the EC cases.
PTEN mutations or sequence alterations were more prominent
in the EC group with endometrioid tumours overrepresented
(Tables 1 and 3) and predominantly of the sort that has great
impact on protein function, such as nonsense mutations or
frameshifts, and clustering mainly at exon 5, with two that fell
within the phosphatase catalytic domain at codons 122–132,
corroborating published observations (Prasad et al, 2005; Bansal
et al, 2009). Residues 233–240 and 308–315 seem to be potential
tyrosine phosphate acceptor sites (Steck et al, 1997), and thus the
nonsense mutation at codon 233 (rs121909219) is associated with
both Bannayan–Zonnana syndrome and Cowden’s disease (Ali
et al, 1999). In addition, several mutations flank closely these
crucial sites, although not within the regions. Some of these were
Arg130Gly rs121909224 and Asp252Val rs121909239, and were all
disease associated in numerous malignancies, among them
endometrial cancer (Cohen et al, 2010).
Only six patients with PTEN alterations were from the TAM
group with five indel and a silent mutation (Table 3). The
difference in the number of patients with PTEN mutation between
the TAM and EC groups was statistically significant with Pp0.05
at the 95% confidence level. This is in agreement with a similar
observation in the literature, where PTEN mutations occurred less
frequently in the tamoxifen-treated patients, although not
statistically significant due to that cohort size (Turbiner et al,
2008).
According to the literature TP53 mutations in endometrial
cancer are more abundant in high-grade tumours with poor
prognosis that are often oestrogen independent (Lax et al, 2000;
Bansal et al, 2009). In our study, most of the TP53 mutations occur
in the serous, clear-cell or serous/clear-cell tumours in the TAM
group. In exon 7, two missense mutations (Arg273His rs28934576
and Arg282Trp rs28934574) were found associated with
Li-Fraumeni syndrome (Malkin et al, 1992; Toguchida et al, 1992).
Only three tumours were of other morphology; i.e., adenocarcinoma,
carcinosarcoma and sarcoma with high-grade FIGO 1B. In the EC
group, a similar pattern emerged, where the majority of TP53
mutations clustered in serous, clear-cell or serous/clear-cell tumours
and only three were in either carcinosarcoma or endometrioid
K-RAS
N = 4
TAM
EC
G>T; 25%
G>A; 75%
T>C; 50% G>A; 50%
T>A; 7%
C>T; 43%
A>G; 22%
T>G; 5%
T>C; 5
%
T>A
; 5%
G>
T; 
10
%G>A
; 7%
Indel; 30%
Indel; 21% Indel; 23%
C>A; 9%
A>T; 9%A>
C;
 
5%
A>
G;
 
5%
C>G; 9%
C>T; 18%
Indel; 83%C>T; 20%
C>T; 17%
A>T; 10%
A>G; 27%
G>
T; 1
0%
G
>A
; 1
0%
K-RAS
N = 2
TP53
N = 10
TP53
N = 14
PTEN
N = 6
PTEN
N = 22
Figure 2. Mutational spectrum of K-RAS, TP53 and PTEN in tumour tissues from TAM and EC patients.
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tumours. In the EC group 38% of the mutations were found in TP53,
with a mix of missense, homoindel and stop mutations. In exon 6
a missense mutation was found with SNP accession number
rs28934575, also present in Li-Fraumeni syndrome (Toguchida
et al, 1992).
It has been reported that TP53 mutations do not concur with
either PTEN (Koul et al, 2002) or K-RAS (Lax et al, 2000)
mutations in endometrial cancer, but rather with loss of p16.
This is in part what has been observed in this study, as virtually
none of the mutations in either of the genes coincided. However, it
has been shown that TP53 gene mutations occur in some
endometrioid endometrial cancers in the presence of PTEN
mutations, suggesting that both these genes participate in the
development of these tumours (Janiec-Jankowska et al, 2010).
Our study supports in part some observations made by Prasad
et al (2005), that endometrial tumours from these two groups
contain similar genetic alterations with regard to the type of gene
mutations. However, the mutational spectrum within some of the
genes is clearly different (Figure 2). Although not much can be said
for K-RAS due to the low occurrence, and the similarities in TP53,
PTEN mutations are quite different between tamoxifen-exposed
and non-exposed cases, suggesting the malignancies arise from
different backgrounds, hence pointing to an effect of tamoxifen.
We have also observed an interesting coincidence between
methylation and mutation, which was regardless of tumour
morphology or genes affected (Table 2). This coincidence was
between 7 of 9 (78%) and 7 of 14 (50%) in TAM and EC,
respectively. The higher occurrence of this in TAM, despite the
significantly lower levels of either alterations in this group, suggests
that there may be an effect of tamoxifen exposure, although a
larger number of cases would be needed to assess this fully. This
suggests that tamoxifen exposure, apart from hormonal effects,
possible adduct forming capacity, may also be driving malignancy
through epigenetic processes.
CONCLUSION
Patients receiving tamoxifen developed more high-grade tumours
with less favourable prognosis. Genes commonly mutated were
TP53 and PTEN, with TP53 being the predominant one in the
TAM cases and PTEN in the EC group. We also confirmed the
presence of MGMT promoter hypermethylation and, in addition, a
coincidence between methylation and mutation in both groups.
The occurrence of this, however, was higher in the TAM group,
although not significantly. Our findings suggest that hypermethy-
lation of MGMT promoter may play an epigenetic role in the
induction of endometrial cancer by tamoxifen.
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